Brukinsa® was the largest of BeOne Medicines Ltd.’s 7 reported lines in fiscal 2025, at $3.93B — 74% of $5.28B.
| Product Name | FY 2020 | FY 2024 | FY 2025 |
|---|---|---|---|
| Brukinsa® | $2.64B | $3.93B | |
| Tevimbra® | $620.84M | $737.30M | |
| Tislelizumab | — | — | |
| Xgeva® | $224.40M | $305.98M | |
| Blincyto® | $74.33M | $104.22M | |
| Kyprolis® | $66.17M | $74.97M | |
| Other | $96.07M | $83.69M | |
| Pobevcy® | $53.51M | $47.40M | |
| Revlimid® | — | — | |
| Vidaza® | — | — | |
| Abraxane® | — | — | |
| Total | $3.78B | $5.28B |
In fiscal 2025, which ended December 31, 2025, the 7 revenue lines BeOne Medicines Ltd. reported in this breakdown added up to $5.28B. That was up 39.8% from $3.78B in fiscal 2024. Brukinsa® was the largest revenue line, at $3.93B or 74.4% of the total, followed by Tevimbra® ($737.30M, 14.0%) and Xgeva® ($305.98M, 5.8%). Together, the two largest revenue lines made up 88.3% of this total.
Compared with fiscal 2024, Brukinsa® grew the fastest, rising 48.6% to $3.93B. Every sizeable revenue line reported in both years grew.
The table also keeps 4 revenue lines that BeOne Medicines Ltd. no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers 3 fiscal years between 2020 and 2025, as reported in BeOne Medicines Ltd.'s annual filings.
United States was the largest of BeOne Medicines Ltd.’s 4 reported lines in fiscal 2025, at $2.84B — 54% of $5.28B.
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $945.55M | $1.95B | $2.84B | |||||||
| U.S | $389.71M | — | — | — | |||||||
| Prc | $840.03M | $1.09B | $1.39B | $1.66B | |||||||
| China | — | — | — | — | |||||||
| Europe- Total Revenue | $48.39M | $122.23M | $359.51M | $609.64M | |||||||
| Other | $10.01M | $28.98M | $78.81M | $171.81M | |||||||
| All Other Countries Except China & The United States Of America | — | — | — | — | |||||||
| Total | $1.29B | $2.19B | $3.78B | $5.28B |
In fiscal 2025, which ended December 31, 2025, the 4 regions BeOne Medicines Ltd. reported in this breakdown added up to $5.28B. That was up 39.8% from $3.78B in fiscal 2024. United States was the largest region, at $2.84B or 53.8% of the total, followed by Prc ($1.66B, 31.4%) and Europe- Total Revenue ($609.64M, 11.5%). Together, the two largest regions made up 85.2% of this total.
Compared with fiscal 2024, Other grew the fastest, rising 118.0% to $171.81M. Every sizeable region reported in both years grew.
The table also keeps 3 regions that BeOne Medicines Ltd. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2015 to 2025, as reported in BeOne Medicines Ltd.'s annual filings.
Tislelizumab was the largest of BeOne Medicines Ltd.’s 3 reported lines in fiscal 2021, at $591.49M — 52% of $1.14B.
| Counterparty Name | FY 2021 |
|---|---|
| Tislelizumab | $591.49M |
| Novartis | $542.30M |
| Ociperlimab | $4.48M |
| Total | $1.14B |
In fiscal 2021, which ended December 31, 2021, the 3 revenue lines BeOne Medicines Ltd. reported in this breakdown added up to $1.14B. Tislelizumab was the largest revenue line, at $591.49M or 52.0% of the total, followed by Novartis ($542.30M, 47.6%) and Ociperlimab ($4.48M, 0.4%). Together, the two largest revenue lines made up 99.6% of this total.
This breakdown covers every fiscal year from 2021 to 2021, as reported in BeOne Medicines Ltd.'s annual filings.
BeOne Medicines Ltd. (ONC) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Brukinsa®, with $3.93B or 74.4% of the total, followed by Tevimbra® at $737.30M (14.0%).
Brukinsa® was BeOne Medicines Ltd.'s largest revenue line in fiscal 2025, with $3.93B in revenue, 74.4% of the $5.28B reported across its 7 revenue lines.
United States was BeOne Medicines Ltd.'s largest region in fiscal 2025, with $2.84B in revenue, 53.8% of the $5.28B reported across its 4 regions.
Of the BeOne Medicines Ltd. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Brukinsa® grew the fastest, rising 48.6% from $2.64B to $3.93B.
Every figure is taken from BeOne Medicines Ltd.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2020 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.